Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, Randomized Phase Ib/II Study of FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer
Conditions
Interventions
FOLFIRI
E7820
+1 more
Locations
34
United States
Rocky Mountain Cancer Center - Midtown
Denver, Colorado, United States
Summit Medical Group
Berkeley Heights, New Jersey, United States
Hematology Oncology Associates SJ P.A.
Mount Holly, New Jersey, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Northwest Medical Specialties, PLLC
Tacoma, Washington, United States
Start Date
March 4, 2010
Primary Completion Date
February 18, 2011
Completion Date
February 18, 2011
Last Updated
November 7, 2023
NCT02600949
NCT07446322
NCT05919264
NCT07541924
NCT07537491
NCT07536113
Lead Sponsor
Eisai Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions